Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings all through the business. Please ship the great phrase—or the dangerous—out of your store to Fraiser Kansteiner, and we are going to characteristic it right here on the finish of every week.
Greene joins Sage as CEO as Jonas swaps to innovation position
Barry Greene took the reins as CEO.
Greene takes the lead at Sage off a 17-year run at Alnylam, the place he most not too long ago served as president. Greene stepped down from that position in September of this 12 months, becoming a member of Sage’s board in October. He succeeds Jeff Jonas, M.D., at Sage, who will stay on the firm within the new position of chief innovation officer. The management change comes a 12 months after destructive section three outcomes with lead pipeline drug zuranolone for main depressive dysfunction hit the corporate onerous, resulting in hypothesis it could possibly be acquired. Biogen is now paying $1.5 billion upfront for a stake in that remedy. Fierce Biotech
Chinese language biotech Zai Lab nabs Roche most cancers veteran as new R&D exec, drug hunter
John Rim was named president and CEO.
Rim takes cost at Samsung Biologics after three years as government vp on the firm. In that position, Rim helped oversee the growth of the corporate’s manufacturing portfolio. Earlier than becoming a member of Samsung in 2018, Rim labored for Genentech/Roche in a variety of senior world management roles, together with in technical operations, product growth and R&D within the U.S. and Europe. Previous to that, he held senior roles at Astellas Prescription drugs typically administration, gross sales and advertising, technical operations, customer support, enterprise growth and strategic planning. Launch
4D hires a trio of space heads because it ramps up its gene remedy pipeline
The corporate tapped Donald Johns, M.D., as chief medical officer and named Katina Dorton chief monetary officer.
Johns takes over as chief medical officer—a task he served in most not too long ago at Syntimmune, the place he was additionally EVP of medical and scientific affairs previous to the corporate’s acquisition by Alexion Prescription drugs. Dorton, in the meantime, has hung out in healthcare, life sciences and funding banking, together with experiences at Repare Therapeutics and AVROBIO. NodThera is advancing a portfolio of potent and selective inhibitors of the NLRP3 inflammasome that cut back each IL-1β and IL-18 pro-inflammatory cytokines—recognized to play a task in continual irritation underpinning a variety of illnesses. The pipeline contains brain-penetrant NLRP3 inhibitors for central nervous system indications. Launch
> Stamford, Connecticut-based SpringWorks Therapeutics promoted Badreddin Edris, Ph.D., presently chief enterprise officer, to chief working officer. In the meantime, the corporate additionally promoted its present SVP of medical analysis and growth, L. Mary Smith, Ph.D., to chief growth officer. Launch
> Boston’s Cardurion Prescription drugs tapped Howard Okay. Surks, M.D., to function chief scientific officer and head of translational drugs. Surks most not too long ago served as head of translational drugs and medical pharmacology, U.S., at Sanofi. Launch
> Swiss biotech AB2 Bio named Djordje Filipovic, Ph.D., as chief business officer on the firm. Filipovic beforehand held a variety of senior roles at Novartis, together with overseeing the event and commercialization of a number of key small molecules and monoclonal antibodies. Launch (PDF)
> San Diego-based Cidara Therapeutics tapped Christopher Kurtz as government vp of technical operations. Earlier than signing up with Cidara, Kurtz was head of economic API manufacturing at Gilead Sciences, the place he had a hand within the latest launches of merchandise like Biktarvy and Veklury. Launch
> McCann Well being promoted its present world president of McCann well being pharmacy advertising, Sandra Carey, to world president, professional audiences.
> Boston-based X4 Prescription drugs appointed Diego Cadavid, M.D., to the position of chief medical officer. Previous to becoming a member of X4, Cadavid was senior vp and head of medical growth at Fulcrum Therapeutics, the place he led growth of a number of small molecules to deal with genetically outlined uncommon illnesses. Launch